1. Giroud M, Scheideler M. Long non-coding RNAs in metabolic organs and energy homeostasis. Int J Mol Sci 2017; 18(12): 2578.
2. Yang W, Lyu Y, Xiang R, Yang J. Long noncoding RNAs in the pathogenesis of insulin resistance. Int J Mol Sci 2022; 23(24): 16054.
3. Aihemaiti G, Song N, Luo J, Liu F, Toyizibai J, Adili N, et al. Targeting lncRNA MALAT1: A Promising Approach to Overcome Metabolic Syndrome. Int J Endocrinol 2024; 2024: 1821252.
4. Zhang H, Niu Q, Liang K, Li X, Jiang J, Bian C. Effect of LncPVT1/miR-20a-5p on lipid metabolism and insulin resistance in NAFLD. Diabetes Metab Syndr Obes 2021; 14: 4599-608.
5. Rajizadeh MA, Moslemizadeh A, Hosseini MS, Rafiei F, Soltani Z, Khoramipour K. Adiponectin receptor 1 could explain the sex differences in molecular basis of cognitive improvements induced by exercise training in type 2 diabetic rats. Sci Rep 2023; 13(1): 16267.
6. Khoramipour K, Rezaei MH, Madadizadeh E, Hosseini MS, Soltani Z, Schierbauer J, et al. High intensity interval training can ameliorate hypothalamic appetite regulation in male rats with type 2 diabetes: the role of Leptin. Cell Mol Neurobiol 2023; 43(8): 4295-307.
7. Khaksari M, Raji-Amirhasani A, Bashiri H, Ebrahimi MN, Azizian H. Protective effects of combining SERMs with estrogen on metabolic parameters in postmenopausal diabetic cardiovascular dysfunction: The role of cytokines and angiotensin II. Steroids 2022; 183: 109023.
8. Ebrahimi MN, Khaksari M, Sepehri G, Karam GA, Raji-Amirhasani A, Azizian H. The effects of alone and combination tamoxifen, raloxifene and estrogen on lipid profile and atherogenic index of ovariectomized type 2 diabetic rats. Life Sci 2020; 263: 118573.
9. Guo W-H, Guo Q, Liu Y-L, Yan D-D, Jin L, Zhang R, et al. Mutated lncRNA increase the risk of type 2 diabetes by promoting β cell dysfunction and insulin resistance. Cell Death Dis 2022; 13(10): 904.
10. Lu Y, Qie D, Yang F, Wu J. LncRNA MEG3 aggravates adipocyte inflammation and insulin resistance by targeting IGF2BP2 to activate TLR4/NF-κB signaling pathway. Int Immunopharmacol 2023; 121: 110467.
11. Tang X, Qin Q, Xu W, Zhang X. Long non-coding RNA TUG1 attenuates insulin resistance in mice with gestational diabetes mellitus via regulation of the MicroRNA-328-3p/SREBP-2/ERK Axis. Diabetes & Metabolism Journal 2023; 47(2): 267-86.
12. Zhu X, Wu Y-B, Zhou J, Kang D-M. Upregulation of lncRNA MEG3 promotes hepatic insulin resistance via increasing FoxO1 expression. Int J Mol Med 2016; 469(2): 319-25.
13. Zhu X, Li H, Wu Y, Zhou J, Yang G, Wang W. lncRNA MEG3 promotes hepatic insulin resistance by serving as a competing endogenous RNA of miR-214 to regulate ATF4 expression. Int J Mol Med 2019; 43(1): 345-57.
14. Chen D-L, Shen D-Y, Han C-K, Tian Y. LncRNA MEG3 aggravates palmitate-induced insulin resistance by regulating miR-185-5p/Egr2 axis in hepatic cells. Eur Rev Med Pharmacol Sci 2019; 23(12): 5456-67.
15. Xing Y-j, Zhang T, Wan S-j, Cheng Y, Zhou S-m, Sun Y, et al. LncRNA HEM2ATM improves obesity-associated adipose tissues meta-inflammation and insulin resistance by interacting with heterogeneous nuclear ribonucleoprotein U. Clin Immunol 2023; 247: 109234.
16. Daneshmoghadam J, Omidifar A, Akbari Dilmaghani N, Karimi Z, Emamgholipour S, Shanaki M. The gene expression of long non‐coding RNAs (lncRNAs): MEG3 and H19 in adipose tissues from obese women and its association with insulin resistance and obesity indices. J Clin Lab Anal 2021; 35(5): e23741.
17. Huang X, Chen J, Li H, Cai Y, Liu L, Dong Q, et al. LncRNA SNHG12 suppresses adipocyte inflammation and insulin resistance by regulating the HDAC9/Nrf2 axis. FASEB J 2024; 38(13): e23794.
18. Geng T, Liu Y, Xu Y, Jiang Y, Zhang N, Wang Z, et al. H19 lncRNA promotes skeletal muscle insulin sensitivity in part by targeting AMPK. Diabetes 2018; 67(11): 2183-98.
19. Gui W, Zhu WF, Zhu Y, Tang S, Zheng F, Yin X, et al. LncRNAH19 improves insulin resistance in skeletal muscle by regulating heterogeneous nuclear ribonucleoprotein A1. Cell Commun Signal 2020; 18(1): 173.
20. Li Y, Cheng X, Li D. LncRNA RPL13p5 gene expression promotes insulin resistance in patients with gestational diabetes. Ann Palliat Med 2021; 10(10): 11024.
21. Xu Y, Kang X, Liu H, Jiang H, Wang W. LncRNA XIST promotes insulin resistance in gestational diabetes mellitus via the microRNA-181b-5p/NDRG2 axis. Gen Physiol Biophys 2023; 42(5): 443-55.
22. Lin H, Xing W, Li Y, Xie Y, Tang X, Zhang Q. Downregulation of serum long noncoding RNA GAS5 may contribute to insulin resistance in PCOS patients. Gynecol Endocrinol 2018; 34(9): 784-8.
23. Zhang Z-M, Liu Z-H, Nie Q, Zhang X-M, Yang L-Q, Wang C, et al. Metformin improves high-fat diet-induced insulin resistance in mice by downregulating the expression of long noncoding RNA NONMMUT031874. 2. E Exp Ther Med 2022; 23(5): 332.
24. Shu L, Hou G, Zhao H, Huang W, Song G, Ma H. Resveratrol improves high-fat diet-induced insulin resistance in mice by downregulating the lncRNA NONMMUT008655. 2. Am J Transl Res 2020; 12(1): 1-18.
25. Liu Z, Zhang Z, Song G, Wang X, Xing H, Wang C. Resveratrol alleviates skeletal muscle insulin resistance by downregulating long noncoding RNA. Int J Endocrinol 2022; 2022: 2539519.
26. Yan C, Li J, Feng S, Li Y, Tan L. Long noncoding RNA Gomafu upregulates Foxo1 expression to promote hepatic insulin resistance by sponging miR-139-5p. Cell Death Dis 2018; 9(3): 289.
27. Yan C, Chen J, Chen N. Long noncoding RNA MALAT1 promotes hepatic steatosis and insulin resistance by increasing nuclear SREBP-1c protein stability. Sci Rep 2016; 6(1): 22640.
28. Liu S-X, Zheng F, Xie K-L, Xie M-R, Jiang L-J, Cai Y. Exercise reduces insulin resistance in type 2 diabetes mellitus via mediating the lncRNA MALAT1/microRNA-382-3p/resistin axis. Mol Ther Nucleic Acids 2019; 18: 34-44.
29. Wang Y, Hu Y, Sun C, Zhuo S, He Z, Wang H, et al. Down‐regulation of Risa improves insulin sensitivity by enhancing autophagy. FASEB J 2016; 30(9): 3133-45.
30. Zhang Y, Gu M, Ma Y, Peng Y. LncRNA TUG1 reduces inflammation and enhances insulin sensitivity in white adipose tissue by regulating miR-204/SIRT1 axis in obesity mice. Mol Cell Biochem 2020; 475(1): 171-83.
31. Valasarajan C, Karger A, Savai R, Pullamsetti SS. Long Noncoding RNAs: Emerging Regulators of Platelet-derived Growth Factor Signaling. Am J Respir Cell Mol Biol 2022; 66(5): 473–5.
32. Singh P, Singh A, Shah S, Vataliya J, Mittal A, Chitkara D. RNA interference nanotherapeutics for treatment of glioblastoma multiforme. Mol Pharm 2020; 17(11): 4040-66.
33. Johannes L, Lucchino M. Current challenges in delivery and cytosolic translocation of therapeutic RNAs. Nucleic Acid Ther 2018; 28(3): 178-93.
34. Huang S, Hao X-Y, Li Y-J, Wu JY, Xiang D-X, Luo S. Nonviral delivery systems for antisense oligonucleotide therapeutics. Biomater Res 2022; 26(1): 49.
35. Li M, Ding X, Zhang Y, Li X, Zhou H, Yang L, et al. Antisense oligonucleotides targeting lncRNA AC104041. 1 induces antitumor activity through Wnt2B/β-catenin pathway in head and neck squamous cell carcinomas. Cell Death Dis 2020; 11(8): 672.
36. Zhang Y, Huang Y-X, Jin X, Chen J, Peng L, Wang D-L, et al. Overexpression of lncRNAs with endogenous lengths and functions using a lncRNA delivery system based on transposon. J Nanobiotechnology 2021; 19(1): 303.
37. Zhang Z, Wan J, Liu X, Zhang W. Strategies and technologies for exploring long noncoding RNAs in heart failure. Biomed Pharmacother 2020; 131: 110572.
38. Wang J-H, Gessler DJ, Zhan W, Gallagher TL, Gao G. Adeno-associated virus as a delivery vector for gene therapy of human diseases. Sig Transduct Target Ther 2024; 9(1): 78.
39. Alhabib NA, Almaniea MA, Alehaidib SM, Almansour MA, Aldosary MS, Almegbel MT, et al. Advanced Drug Delivery Systems for Enhancing the Efficacy of RNA-based Therapeutics. Int J Health Sci 2022; 6(S10): 1659-83.
Miranda-Castro R, de-Los-Santos-Álvarez N, Lobo-Castañón MJ. Long noncoding RNAs: from genomic junk to rising stars in the early detection of cancer. Anal Bioanal Chem 2019; 411(19): 4265-75.
